Advertisement

Tumor Biology

, Volume 37, Issue 6, pp 7453–7459 | Cite as

Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma

  • Yi Gao
  • Ning Qu
  • Ling Zhang
  • Jia-ying Chen
  • Qing-hai JiEmail author
Research Article

Abstract

The purpose of this study was to describe the ultrasonography (US) image features and preoperative thyroid-stimulating hormone (TSH) level in patients with thyroid nodules read as or suspicious for papillary thyroid microcarcinoma (PTMC) on US-guided fine-needle aspiration biopsy (US-FNAB) and to identify the risk factors for central lymph node metastasis (CLNM) that can guide surgical strategies for patients diagnosed with PTMC on pathology. In this retrospective cross-sectional study, a total of 163 patients diagnosed cytologically and histopathologically were included. Cytological diagnosis for each patient preoperatively was based on the Bethesda classification for the nodule: 44 (27.0 %) were suspicious for papillary carcinoma (Bethesda V) and 119 (73.0 %) were positive for papillary carcinoma (Bethesda VI). PTMC was confirmed in 162 patients on pathology. In the multivariate analysis, the US suspicious images including nodal metastases, microcalcification, and irregular margins, tumor size larger than 7 mm on US, and serum TSH level equal to or greater than 2.5 mIU/L were independent predictors for CLNM in 162 patients diagnosed with PTMC. Prophylactic central lymph node dissection (CLND) may be considered in PTMC patients presenting with risk factors.

Keywords

Papillary thyroid microcarcinoma Lymph node metastasis Ultrasonography Thyroid-stimulating hormone Prediction 

Abbreviations

PTC

Papillary thyroid cancer

PTMC

Papillary thyroid microcarcinoma

US

Ultrasonography

US-FNAB

US-guided fine-needle aspiration biopsy

TSH

Thyroid-stimulating hormone

CLNM

Central lymph node metastasis

LLNM

Lateral lymph node metastasis

CLND

Central lymph node dissection

LLND

Lateral lymph node dissection

OR

Odds ratio

CI

Confidence interval

Notes

Acknowledgments

This research is supported by grants from the National Natural Science Foundation of China (81272934) and the Natural Science Foundation of Shanghai (12ZR1406800).

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Malandrino PPG, Attard M. Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab. 2013;2013(98):1427–34.CrossRefGoogle Scholar
  4. 4.
    Lee J, Park JH, Lee CR, Chung WY, Park CS. Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid. 2013;23:1408–15.CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, Wang Y, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012;97:1250–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399–407.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg. 2004;28:498–501.CrossRefPubMedGoogle Scholar
  8. 8.
    Choi YJ, Yun JS, Kook SH, Jung EC, Park YL. Clinical and imaging assessment of cervical lymph node metastasis in papillary thyroid carcinomas. World J Surg. 2010;34:1494–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:489–94. discussion 494-486.CrossRefPubMedGoogle Scholar
  10. 10.
    Zafon C, Obiols G, Mesa J. Preoperative TSH level and risk of thyroid cancer in patients with nodular thyroid disease: nodule size contribution. Endocrinol Nutr. 2014;9:28–32.Google Scholar
  11. 11.
    Negro R, Valcavi R, Toulis KA. Incidental thyroid cancer in toxic and nontoxic goiter: is TSH associated with malignancy rate? Results of a meta-analysis. Endocr Pract. 2013;19:212–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Smith VE, Franklyn JA, McCabe CJ. Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake. J Endocrinol. 2011;210:157–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009;69:8317–25.CrossRefPubMedGoogle Scholar
  14. 14.
    Pusztaszeri MP, Krane JF, Cibas ES, Daniels G, Faquin WC. FNAB of benign thyroid nodules with papillary hyperplasia: a cytological and histological evaluation. Cancer Cytopathol. 2014;122:666–77.CrossRefPubMedGoogle Scholar
  15. 15.
    Sidoti M, Marino G, Resmini E, Augeri C, Cappi C, Cavallero D, et al. The rational use of fine needle aspiration biopsy (FNAB) in diagnosing thyroid nodules. Minerva Endocrinol. 2006;31:159–72.PubMedGoogle Scholar
  16. 16.
    Baloch Z, LiVolsi VA, Jain P, Jain R, Aljada I, Mandel S, et al. Role of repeat fine-needle aspiration biopsy (FNAB) in the management of thyroid nodules. Diagn Cytopathol. 2003;29:203–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC. The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid. 2009;19:1215–23.CrossRefPubMedGoogle Scholar
  18. 18.
    Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRefPubMedGoogle Scholar
  19. 19.
    Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health And Nutrition Examination Survey (NHANES iii). J Clin Endocrinol Metab. 2002;87:489–99.CrossRefPubMedGoogle Scholar
  20. 20.
    Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43:55–68.CrossRefGoogle Scholar
  21. 21.
    Byun BH, Jeong UG, Hong SP, Min JJ, Chong A, Song HC, et al. Prediction of central lymph node metastasis from papillary thyroid microcarcinoma by 18f-fluorodeoxyglucose PET/CT and ultrasonography. Ann Nucl Med. 2012;26:471–7.CrossRefPubMedGoogle Scholar
  22. 22.
    So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010;148:526–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Rosen IB, Azadian A, Walfish PG, Salem S, Lansdown E, Bedard YC. Ultrasound-guided fine-needle aspiration biopsy in the management of thyroid disease. Am J Surg. 1993;166:346–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006;16:47–53.CrossRefPubMedGoogle Scholar
  25. 25.
    Ogilvie JB, Patel KN, Heller KS. Impact of the 2009 American Thyroid Association guidelines on the choice of operation for well-differentiated thyroid microcarcinomas. Surgery. 2010;148:1222–6. discussion 1226-1227.CrossRefPubMedGoogle Scholar
  26. 26.
    Ito Y, Kobayashi K, Tomoda C, Uruno T, Takamura Y, Miya A, et al. Ill-defined edge on ultrasonographic examination can be a marker of aggressive characteristic of papillary thyroid microcarcinoma. World J Surg. 2005;29:1007–11. discussion 1011-1002.CrossRefPubMedGoogle Scholar
  27. 27.
    Kim TY, Hong SJ, Kim JM, Kim WG, Gong G, Ryu JS, et al. Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer. 2008;8:296.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lim YC, Choi EC, Yoon YH, Kim EH, Koo BS. Central lymph node metastases in unilateral papillary thyroid microcarcinoma. Br J Surg. 2009;96:253–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Moon HJ, Kim EK, Yoon JH, Kwak JY. Clinical implication of elastography as a prognostic factor of papillary thyroid microcarcinoma. Ann Surg Oncol. 2012;19:2279–87.CrossRefPubMedGoogle Scholar
  30. 30.
    Satta MA, De Rosa G, Testa A, Maussier ML, Valenza V, Rabitti C, et al. Thyroid cancer in suppressed contralateral lobe of patients with hot thyroid nodule. Eur J Cancer. 1993;29A:1190–2.CrossRefPubMedGoogle Scholar
  31. 31.
    Carayon P, Thomas-Morvan C, Castanas E, Tubiana M. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab. 1980;51:915–20.CrossRefPubMedGoogle Scholar
  32. 32.
    Ichikawa Y, Saito E, Abe Y, Homma M, Muraki T. Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab. 1976;42:395–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91:4295–301.CrossRefPubMedGoogle Scholar
  34. 34.
    Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996;335:99–107.CrossRefPubMedGoogle Scholar
  35. 35.
    Jara SM, Carson KA, Pai SI, Agrawal N, Richmon JD, Prescott JD, et al. The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma. Surgery. 2013;154:1272–80. discussion 1280-1272.CrossRefPubMedGoogle Scholar
  36. 36.
    Kim YS, Choi HJ, Kim ES. Papillary thyroid carcinoma with thyroiditis: lymph node metastasis, complications. J Korean Surg Soc. 2013;85:20–4.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kim SS, Lee BJ, Lee JC, Kim SJ, Jeon YK, Kim MR, et al. Coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck. 2011;33:1272–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yi Gao
    • 1
    • 3
  • Ning Qu
    • 2
    • 3
  • Ling Zhang
    • 2
    • 3
  • Jia-ying Chen
    • 2
    • 3
  • Qing-hai Ji
    • 2
    • 3
    Email author
  1. 1.Department of UltrasonographyFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Head and Neck SurgeryFudan University Shanghai Cancer CenterShanghaiChina
  3. 3.Department of OncologyShanghai Medical College, Fudan UniversityShanghaiChina

Personalised recommendations